Literature DB >> 15081094

The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.

Irem Dinçer1, Alper Ergin, Tanil Kocagöz.   

Abstract

In vitro activity of beta-lactam antibiotics and their beta-lactamase inhibitor combinations were evaluated for their activity against clinical isolates of Mycobacterium tuberculosis and M. tuberculosis H37Ra. Agar dilution, the BACTEC 460 system and beta-lactamase activity tests were used. Results using the BACTEC 460 and enzyme activity tests showed the best beta-lactamase inhibitor for M. tuberculosis H37Ra to be clavulanic acid. Cefazolin-clavulanic acid gave the lowest minimal inhibitory concentration (MIC) values using dilution tests and M. tuberculosis H37Ra. beta-Lactam antibiotics were combined with clavulanic acid and tested for in vitro activity against 50 selected multidrug-resistant (MDR) and 50 susceptible clinical isolates. Seventy-four percent of the isolates were inhibited by cefazolin-clavulanic acid combination. These results suggested that an appropriate combination of beta-lactam and beta-lactamase inhibitors might be useful in the treatment of tuberculosis due to multidrug-resistant strains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081094     DOI: 10.1016/j.ijantimicag.2003.09.023

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  11 in total

1.  Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors:  Feng Wang; Craig Cassidy; James C Sacchettini
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  The role of the β5-α11 loop in the active-site dynamics of acylated penicillin-binding protein A from Mycobacterium tuberculosis.

Authors:  Alena Fedarovich; Robert A Nicholas; Christopher Davies
Journal:  J Mol Biol       Date:  2012-02-23       Impact factor: 5.469

3.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

4.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

5.  Unusual conformation of the SxN motif in the crystal structure of penicillin-binding protein A from Mycobacterium tuberculosis.

Authors:  Alena Fedarovich; Robert A Nicholas; Christopher Davies
Journal:  J Mol Biol       Date:  2010-03-03       Impact factor: 5.469

6.  Synthesis of labeled meropenem for the analysis of M. tuberculosis transpeptidases.

Authors:  David B Kastrinsky; Clifton E Barry
Journal:  Tetrahedron Lett       Date:  2010       Impact factor: 2.415

7.  Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors:  Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal:  Protein Sci       Date:  2014-12-30       Impact factor: 6.725

Review 8.  Reappraising the use of β-lactams to treat tuberculosis.

Authors:  Sebastian G Kurz; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

9.  Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.

Authors:  Jean-Emmanuel Hugonnet; Lee W Tremblay; Helena I Boshoff; Clifton E Barry; John S Blanchard
Journal:  Science       Date:  2009-02-27       Impact factor: 47.728

10.  Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.

Authors:  Yu-Tzu Tseng; Yu-Chung Chuang; Chin-Chung Shu; Chien-Ching Hung; Chiung-Fang Hsu; Jann-Yuan Wang
Journal:  Crit Care       Date:  2012-10-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.